Novartis reveals strong long-term data Cosentyx in psoriasis of the hands and feet
pharmafile | December 1, 2017 | News story | Medical Communications, Research and Development | Cosentyx, Novartis, palmoplantar psoriasis, pharma, psoriasis
Novartis has released new data for Consentyx (secukinumab) which it claims make the IL-17A inhibitor “the first biologic to show long-term efficacy in nail and palmoplantar psoriasis”.
The data drawn from two late-stage studies – including the largest and longest randomized controlled trial to date in palmoplantar psoriasis patients – showed that 59% and 53% of patients who received Cosentyx in 300mg or 150mg doses respectively achieved total clearance or near-total clearance of palms and soles at 2.5 years, according to by Palmoplantar Investigator’s Global Assessment (ppIGA). Additionally, the therapy led to a 73% and 63% improvement from baseline in the same doses on the Nail Psoriasis Severity Index (NAPSI).
Nail and palmoplantar psoriasis affect the hands and soles of the feet and can occur in up to 90% of patients with the wider condition, leading to reduced mobility, discomfort and functional impairment.
Novartis’ Global Development Unit Head, Immunology & Dermatology, Eric Hughes, commented: “Patients with nail and palmoplantar psoriasis need effective treatment options to address the significant impact these conditions can have on their day-to-day lives/ As an IL-17A inhibitor, Cosentyx provides a highly targeted treatment option that can not only effectively treat the plaques caused by psoriasis, as evident by recently presented 5-year data, but also hard-to-treat forms and associated arthritic conditions.”
Consentyx is currently approved in over 80 countries as a treatment for moderate-to-severe plaque psoriasis. In the US, it is approved with the caveat that it is used in adult patients who are candidates for systemic therapy or phototherapy.
Matt Fellows
Related Content
Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
Novartis candidate for Sjögren’s disease presents positive results
Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 …
